BCMA is becoming recognized as a promising target in multiple myeloma. In particular, BCMA-specific CAR T cell therapy is becoming an exciting and promising area of research.
In this presentation, we will show exciting new Anti-BCMA Antibody candidates discovered using SCT’s AbTheneum platform. We will be sharing data from validation tests including ELISA, cell-binding by flow cytometry, affinity measurement using BiaCore, and ADCC activity. The discovery of these high-quality and therapeutically relevant antibody candidates highlights some of the power in AbTheneum.
AbTheneum is SCT’s antibody discovery technology platform. We screen thousands of antibody-secreting cells for binding characteristics and sequence all the cells to return native heavy and light chain sequence pairs correlated with the binding activity for each cell. AbTheneum screening assay is flexible and can be customized for your target to find cross-reactivity, epitope binning, subclass characterization, and more.
- Current case studies of validated antibodies discovered by SCT
- Advantages of using AbTheneum for antibody discovery for rare antibodies
- Applications for AbTheneum’s screening assay (cross-reactivity, epitope binning, specificity, etc.)
Chun-Nan Chen, Ph.D.
Chief Scientific Officer
Single Cell Technology
Chun-Nan Chen, Ph.D., is Chief Executive Officer and Chief Scientific Officer of SCT. Dr. Chen is a research scientist and business manager with twenty years of experience. At Applied Biosystems in charge of human genome mapping, he had extensive collaboration with senior research labs worldwide, and was in charge of personnel, budgeting, planning, scheduling, operations and quality control. Dr. Chen was a visiting scholar at Yang Ming University, a member of Taiwan’s National Science Council on Biotechnology, and an adviser for the Executive Yuan. He was also an invited speaker at numerous scientific meetings both in Taiwan and the United States, taught the Advanced Genome Sequence Analysis course at Cold Spring Harbor Laboratory.
Dr. Chen received his postdoctoral training in Biochemistry Molecular Biology from UC San Francisco, his Ph.D. from Michigan State University, and his B.S. from National Taiwan University, and held senior scientific positions at Celera Genomics, Applied Biosystems, Pharmageneis, SyStemix and DesignRx Pharmaceuticals. Dr. Chen is a registered United States Patent Agent.
Chief Operating Officer
Single Cell Technology
Allison Schulkins has experience in molecular biology, experimental design, fluid dynamics, and project management. She has spent years leading efforts to improve and validate SCT’s processes for cell isolation, antibody screening, and amplification techniques for Next Generation Sequencing. She has used her expertise across SCT’s converging fields to manage laboratory operations and client projects. Ms. Schulkins has a B.S. in Biochemistry from the University of California, Santa Barbara and a M.S. in Chemical Engineering from San Jose State University. She has laboratory experience in cloning, enzymatic processes, biopolymers, and chemical finishing.
Cost: No Cost!